Scientific Industries (SCND) Q4 2025 earnings summary

Executive summary

• Designs, manufactures, and markets benchtop laboratory equipment and bioprocessing systems, with operations in the US and Germany.

• Sold the Genie Division in August 2025, focusing on Torbal® and VIVID® product lines and bioprocessing systems.

• Bioprocessing segment remains in start-up phase, requiring ongoing investment and incurring losses.

Financial highlights

• Net revenues for 2025 increased 5.4% to $5.05M from $4.80M in 2024, driven by Torbal® sales.

• Gross profit margin fell to 25.8% from 41.8% due to inventory write-offs in bioprocessing; adjusted margin would have been 42.6%.

• Net loss for 2025 was $1.22M, a significant improvement from $6.45M loss in 2024, aided by a $5.26M gain on the Genie Division sale.

• Cash and cash equivalents rose to $955K at year-end 2025 from $588K in 2024.

• Accumulated deficit stood at $35.15M as of December 31, 2025.

Outlook and guidance

• Management expects continued negative cash flows from operations as bioprocessing investments persist.

• Cash from the Genie Division sale and related agreements is expected to fund operations for at least one year.

• Future profitability depends on expense reduction, revenue growth, or additional capital.